162 related articles for article (PubMed ID: 28554575)
1. Dyrk1B overexpression is associated with breast cancer growth and a poor prognosis.
Chen Y; Wang S; He Z; Sun F; Huang Y; Ni Q; Wang H; Wang Y; Cheng C
Hum Pathol; 2017 Aug; 66():48-58. PubMed ID: 28554575
[TBL] [Abstract][Full Text] [Related]
2. The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer.
Gao J; Yang X; Yin P; Hu W; Liao H; Miao Z; Pan C; Li N
Int J Oncol; 2012 Apr; 40(4):1203-9. PubMed ID: 22159921
[TBL] [Abstract][Full Text] [Related]
3. Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells.
Gao J; Zheng Z; Rawal B; Schell MJ; Bepler G; Haura EB
Cancer Biol Ther; 2009 Sep; 8(17):1671-9. PubMed ID: 19633423
[TBL] [Abstract][Full Text] [Related]
4. Both high expression of pyruvate kinase M2 and vascular endothelial growth factor-C predicts poorer prognosis in human breast cancer.
Lin Y; Liu F; Fan Y; Qian X; Lang R; Gu F; Gu J; Fu L
Int J Clin Exp Pathol; 2015; 8(7):8028-37. PubMed ID: 26339369
[TBL] [Abstract][Full Text] [Related]
5. Alternative splicing variants of dual specificity tyrosine phosphorylated and regulated kinase 1B exhibit distinct patterns of expression and functional properties.
Leder S; Czajkowska H; Maenz B; De Graaf K; Barthel A; Joost HG; Becker W
Biochem J; 2003 Jun; 372(Pt 3):881-8. PubMed ID: 12633499
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of ILK1 in breast cancer associates with poor prognosis.
Yang HJ; Zheng YB; Ji T; Ding XF; Zhu C; Yu XF; Ling ZQ
Tumour Biol; 2013 Dec; 34(6):3933-8. PubMed ID: 23832543
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor.
Zeng Z; Lin H; Zhao X; Liu G; Wang X; Xu R; Chen K; Li J; Song L
Clin Cancer Res; 2012 Aug; 18(15):4059-69. PubMed ID: 22675169
[TBL] [Abstract][Full Text] [Related]
8. Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer.
Wu J; Zhang S; Shan J; Hu Z; Liu X; Chen L; Ren X; Yao L; Sheng H; Li L; Ann D; Yen Y; Wang J; Wang X
Cancer Lett; 2016 Jul; 376(2):284-92. PubMed ID: 27063096
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
[TBL] [Abstract][Full Text] [Related]
10. Elevated Expression of RIOK1 Is Correlated with Breast Cancer Hormone Receptor Status and Promotes Cancer Progression.
Huang Z; Li X; Xie T; Gu C; Ni K; Yin Q; Cao X; Zhang C
Cancer Res Treat; 2020 Oct; 52(4):1067-1083. PubMed ID: 32599985
[TBL] [Abstract][Full Text] [Related]
11. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
[TBL] [Abstract][Full Text] [Related]
12. Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
Mimoto R; Nihira NT; Hirooka S; Takeyama H; Yoshida K
Cancer Lett; 2017 Jan; 384():27-38. PubMed ID: 27746162
[TBL] [Abstract][Full Text] [Related]
13. Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.
Guo X; Wang X; Wang Z; Banerjee S; Yang J; Huang L; Dixon JE
Nat Cell Biol; 2016 Feb; 18(2):202-12. PubMed ID: 26655835
[TBL] [Abstract][Full Text] [Related]
14. E2F8 confers cisplatin resistance to ER+ breast cancer cells via transcriptionally activating MASTL.
Tian J; Lin Y; Yu J
Biomed Pharmacother; 2017 Aug; 92():919-926. PubMed ID: 28605876
[TBL] [Abstract][Full Text] [Related]
15. SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients.
Chan HJ; Li H; Liu Z; Yuan YC; Mortimer J; Chen S
Oncotarget; 2015 Sep; 6(28):25815-27. PubMed ID: 26158350
[TBL] [Abstract][Full Text] [Related]
16. NBAT1 suppresses breast cancer metastasis by regulating DKK1 via PRC2.
Hu P; Chu J; Wu Y; Sun L; Lv X; Zhu Y; Li J; Guo Q; Gong C; Liu B; Su S
Oncotarget; 2015 Oct; 6(32):32410-25. PubMed ID: 26378045
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.
Imawari Y; Mimoto R; Hirooka S; Morikawa T; Takeyama H; Yoshida K
Cancer Sci; 2018 Feb; 109(2):363-372. PubMed ID: 29193658
[TBL] [Abstract][Full Text] [Related]
18. miRNA-223 suppresses FOXO1 and functions as a potential tumor marker in breast cancer.
Wei YT; Guo DW; Hou XZ; Jiang DQ
Cell Mol Biol (Noisy-le-grand); 2017 May; 63(5):113-118. PubMed ID: 28719355
[TBL] [Abstract][Full Text] [Related]
19. ANLN is a prognostic biomarker independent of Ki-67 and essential for cell cycle progression in primary breast cancer.
Magnusson K; Gremel G; Rydén L; Pontén V; Uhlén M; Dimberg A; Jirström K; Pontén F
BMC Cancer; 2016 Nov; 16(1):904. PubMed ID: 27863473
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of BMP6 enhances cell proliferation and chemoresistance via activation of the ERK signaling pathway in breast cancer.
Lian WJ; Liu G; Liu YJ; Zhao ZW; Yi T; Zhou HY
Oncol Rep; 2013 Jul; 30(1):193-200. PubMed ID: 23674072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
